Skip to main contentAI and Advanced
/
KPL · NSEMarket ticker unavailable · configure an authorised index feed
KP
NSE · Equity shares · Biotechnology & Drugs-33.10 · -0.97%
Kwality Pharmaceuticals KPL
NSE:INR 3,394.9
BSE:INR 2,692.35
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for KPL
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 3,428
Day rangeINR 3,137 — INR 3,477.2
52-week rangeINR 1,561 — INR 3,798.9
Volume81,998
Market cap2,787.61
P/E41.4
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)503.08
Net Income (INR Cr)67.35
Rev Growth (5 Year %)13.94
EPS Growth (5 Year %)34.77
P/E Ratio41.4
Book Value313.94
EPS65.5
Price/BV10.81Computed
Research path: Interpret Kwality Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
KPLKwality Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 592.21 | 447.27 | 394.21 |
| Cash Equivalents | 2.86 | 2.74 | 3.69 |
| Other Liabilities Total | 7.37 | 0.25 | 0.22 |
| Long Term Debt | 29.4 | 15.12 | 19.56 |
| Common Stock Total | 10.38 | 10.38 | 10.38 |
| Other Current Assets Total | 43.78 | 12.8 | 19.03 |
| Total Assets | 592.21 | 447.27 | 394.21 |
| Current Portof LT Debt/Capital Leases | 101.06 | 13.99 | 12.54 |
| Cash | 0.74 | 12.02 | 2.26 |
| Total Equity | 331.6 | 264.05 | 224.21 |
| Retained Earnings(Accumulated Deficit) | 321.22 | 244.4 | 204.6 |
| Total Common Shares Outstanding | 1.04 | 1.04 | 1.04 |
| Tangible Book Valueper Share Common Eq | 313.94 | 252.83 | 216.08 |
| Total Liabilities | 260.61 | 183.22 | 170 |
| Total Debt | 130.46 | 112.45 | 98.12 |
| Cashand Short Term Investments | 3.59 | 14.76 | 5.94 |
| Total Receivables Net | 280.05 | 164.85 | 127.13 |
| Accounts Receivable-Trade Net | 280.05 | 154.31 | 114.39 |
| Property/Plant/Equipment Total-Net | 166.73 | 143.98 | 139.05 |
| Minority Interest | -1.67 | -1.65 | -1.63 |
| Total Current Liabilities | 225.52 | 169.51 | 151.85 |
| Total Inventory | 78.25 | 91.38 | 90.59 |
| Accounts Payable | 101.69 | 55.79 | 44.32 |
| Other Currentliabilities Total | 22.77 | 16.22 | 28.78 |
| Total Long Term Debt | 29.4 | 15.12 | 19.56 |
| Intangibles Net | 5.85 | 1.71 | Not available |
| Other Long Term Assets Total | 13.95 | 6.27 | 1.09 |
| Total Current Assets | 405.68 | 283.78 | 242.69 |
| Accumulated Depreciation Total | Not available | -85.29 | -67.03 |
| Accrued Expenses | Not available | 0.16 | 0.19 |
| Additional Paid-In Capital | Not available | 8.47 | 8.47 |
| Long Term Investments | Not available | 0 | 0 |
| Property/Plant/Equipment Total-Gross | Not available | 228.04 | 205.21 |
| Notes Payable/Short Term Debt | Not available | 83.33 | 66.02 |
| Deferred Income Tax | Not available | 0 | 0 |
| Note Receivable-Long Term | Not available | 11.53 | 11.38 |
| Unrealized Gain(Loss) | Not available | 0.8 | 0.8 |
| Other Equity Total | Not available | Not available | -0.04 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.8
Price to Sale Ratio5.54
Growth
Debt 5Yr CAGR %25.91
Margins
Operating Margin 12m19.4
Operating Margin 5y Avg20.61
Net Profit Margin 12m13.39
Net Profit Margin 5y14.3
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk59.18
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,939 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,369.5 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,976.15 | 1.68 L | 72.73 | — |
| Cipla | INR 1,410.7 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,123.65 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 54.86%
- FII
- 3.13%
- Other
- 42.01%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Kwality Pharmaceuticals Appoints Legal Expert Swanith Kapoor as Independent Director - psuindia.comMarket news · 3 Jun 2026, 11:02 am
Kwality Pharmaceuticals Appoints Legal Expert Swanith Kapoor as Independent Director psuindia.com
Kwality Pharmaceuticals Ltd Hits All-Time High of Rs 1,782 as Momentum Builds Across Timeframes - Markets MojoMarket news · 3 Jun 2026, 2:48 am
Kwality Pharmaceuticals Ltd Hits All-Time High of Rs 1,782 as Momentum Builds Across Timeframes Markets Mojo
Kwality Pharmaceuticals Ltd is Rated Buy - Markets MojoMarket news · 3 Jun 2026, 2:42 am
Kwality Pharmaceuticals Ltd is Rated Buy Markets Mojo
Kwality Pharmaceuticals | Stock Share Price Live - MarketSmith IndiaMarket news · 2 Jun 2026, 10:07 pm
Kwality Pharmaceuticals | Stock Share Price Live MarketSmith India
Kwality Pharmaceuticals appoints Swanith Kapoor as Independent Director - scanx.tradeMarket news · 2 Jun 2026, 5:43 pm
Kwality Pharmaceuticals appoints Swanith Kapoor as Independent Director scanx.trade
FIIs bet on high-growth smallcaps: 14 stocks rally up to 225% in 5 months, 6 turn multibaggers - The Economic TimesMarket news · 1 Jun 2026, 4:33 pm
FIIs bet on high-growth smallcaps: 14 stocks rally up to 225% in 5 months, 6 turn multibaggers The Economic Times
Corporate actions
Events
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Kwality Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Kwality Pharmaceuticals Limited is an India-based company, which engages in the manufacturing & trading in pharmaceuticals & allied products. It engages in the business of manufacturers, buyers and sellers of and dealers in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. It also engages in research and development activities. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company has approximately 48 different sections available at their production centers. Its subsidiary is Kwality Pharmaceuticals Africa Limitada.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- KPL
- BSE Code
- 539997
Questions
Stock FAQ
What is the symbol and ISIN of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has the symbol KPL and ISIN - INE552U01010.
What is the current price of Kwality Pharmaceuticals?
Kwality Pharmaceuticals is currently trading at INR 3,394.90.
What are the year high and year low of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a year high of INR 3,798.90 and a year low of INR 1,561.00.
What is the market capitalization of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a market capitalization of INR 2,787.61 crore.
What is the P/E ratio of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a P/E ratio of 41.40.
What is the dividend yield of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a dividend yield of 0.00%.
How is the financial performance of Kwality Pharmaceuticals based on revenue, net income, and EPS?
Kwality Pharmaceuticals has revenue of INR 503.08 crore, net income of INR 67.35 crore, and EPS of INR 65.47.
What is the book value of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a book value of INR 313.94.
What is the debt-to-equity ratio of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Kwality Pharmaceuticals?
Kwality Pharmaceuticals has a price-to-book ratio of 10.81 and a price-to-sales ratio of 5.54.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.